Breakthrough trial aims to free kidney transplant patients from lifelong medications
Disease control
Ongoing
This study is testing whether a drug called TCD601 (Siplizumab), combined with donor bone marrow cells and mild chemotherapy, can help kidney transplant recipients safely reduce or stop their lifelong anti-rejection medications. The goal is to help the body accept the new kidney …
Phase: PHASE2 • Sponsor: ITB-Med LLC • Aim: Disease control
Last updated Apr 17, 2026 16:10 UTC